# Organogenesis (ORGO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ORGO
## Company Profile
- Ticker: ORGO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.41 USD
- Market cap: 288230987.52000004 USD
- Last updated: 2026-08-06
## Business Overview
### Regenerative Medicine
Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures.
### Advanced Wound Care
The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and complex wounds.
### Surgical and Sports Medicine
Organogenesis also supplies products for orthopedic, sports-medicine and surgical applications, where its biologic materials are used to support soft-tissue repair and healing.
## Why The Stock Is Moving

The latest monitored company update is “Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Organogenesis’s catalysts are PuraPly, Affinity, and the broader wound-care and surgical portfolio. The business moves on adoption, reimbursement, and product-mix execution.

## Recent News
- 2026-08-06 20:05 EST — [Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2026-financial-results-9a026aba) — Source: Organogenesis
- 2026-07-27 20:05 EST — [Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers](https://biopharmsignal.com/news/ORGO/organogenesis-announces-publication-of-peer-reviewed-clinical-trial-results-demo-4f52441f) — Source: Organogenesis
- 2026-07-09 11:30 EST — [Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-to-report-second-quarter-of-fiscal-year-2026-financia-0a1983ce) — Source: Organogenesis
- 2026-07-06 20:05 EST — [Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis](https://biopharmsignal.com/news/ORGO/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-dd638fde) — Source: Organogenesis
- 2026-05-07 20:06 EST — [Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-first-quarter-2026-financial-results) — Source: Organogenesis